Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US7067138B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2000 |
| Grant date | Jun 27, 2006 |
| Priority date | — |
| Expiry date | Dec 15, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/824
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.